We sought to investigate whether the use of balanced solutions reduces the incidence of hyperchloraemic acidosis without increasing the risk for intracranial hypertension in patients with severe brain injury.
Introduction
Brain injuries remain a major concern for public health services, particularly because of the high mortality rate and long-term disabilities that result [1] . In the early stages of caring for brain-injured patients, therapies are focused on minimising secondary brain injuries that are centrally involved in determining outcomes [2] . Intracranial hypertension (ICH) is the most frequent cause of death and secondary brain insults after brain injury [3] . The maintenance of adequate cerebral perfusion pressure (CPP), which is associated with control of intracranial pressure (ICP), is the cornerstone of treating the ion deficit associated with brain ischaemia in brain-injured patients. Infusion of hypo-osmotic solutions, which increases cerebral swelling, should be avoided after brain injury [4, 5] . Current recommendations are to use isotonic solutions in patients with severe brain injury [6, 7] , with isotonic sodium chloride (0.9% saline solution) being the mainstay of therapy. Isotonic sodium chloride solutions induce hyperchloraemic metabolic acidosis and have side effects including haemostatic alterations, cognitive dysfunction and ileus [8] .
Hyperchloraemia is relatively common in critically ill patients, and it is now commonly accepted that chloriderich fluids are the primary cause of hyperchloraemic acidosis in critically ill patients [9] . In a before-after study, a chloride-restrictive strategy was associated with a significant decrease in renal failure in critically patients and significantly affected electrolyte and acid-base status [10] . In a post hoc analysis of a retrospective study in TBI patients receiving isotonic sodium chloride solutions for basal infusion [11] , 65% of the patients experienced hyperchloraemia. Chloride channels regulate cell oedema [12] , and it could be hypothesised that dyschloraemia contributes to brain swelling.
Isotonic balanced solutions are now available and include crystalloids as well as hydroxyethyl starch (HES) solutions. In these isotonic solutions, the use of malate and acetate allows the reduction of chloride concentration while ensuring isotonicity. Balanced solutions could thus reduce the incidence of hyperchloraemic metabolic acidosis. Balanced solutions decrease the rate of hyperchloraemic acidosis in healthy volunteers [13, 14] and during perioperative care compared with saline solutions [15] [16] [17] . To date, no data regarding isotonic balanced solutions for brain-injured patients have been published, and use of these solutions is therefore not recommended in this setting. The use of a balanced solution would appear to be attractive in brain-injured patients who are prone to ion homeostasis disruption, notably through hormonal dysfunction such as diabetes insipidus or cerebral salt-wasting syndrome or through alterations of chloride-dependent channels such as the NKCC1 transporter [18, 19] . We postulated that infusion of isotonic balanced solutions instead of saline solutions would diminish the incidence of hyperchloraemic acidosis without increasing ICP in patients with severe brain injury hospitalised in the ICU.
Materials and methods

Ethical approval and study design
This randomised, double-blind, parallel, controlled study was approved by the Institutional Review Board of Tours, France (Région Centre, Ouest-1) (Trial registration: EudraCT 2008-004153-15 and NCT00847977). Patients were enrolled after their next-of-kin provided written informed consent. Retrospective consent, when available, was obtained from patients. Patients were enrolled from October 2008 to October 2010, when recruitment was completed in three ICUs of the Nantes University Hospital.
Patient population
Patients with severe traumatic brain injury (TBI) (Glasgow Coma Scale score ≤8) on mechanical ventilation within the first 12 hours after brain injury were included. During recruitment, we refined the eligibility criteria by including patients with subarachnoid haemorrhage (SAH) at World Federation of Neurosurgical Societies (WFNS) grade III or worse (amendment of 26 July 2010). Exclusion criteria were multiple trauma, pregnancy, azotaemia above 200 μmol/L, kalemia less than 2.5 mmol/L, calcaemia less than 1.8 mmol/L, HES hypersensitivity, haemophilia or von Willebrand disease. Patients were also excluded when hypertonic saline solutions (HSSs) were used prior to inclusion or within the first 6 hours of the study start.
Randomisation
Patients were randomised in a 1:1 ratio to either the balanced group (allocated solutions, crystalloids: Isofundine/HES: Tetraspan; B Braun Medical, Melsungen, Germany) or the saline group (allocated solutions, crystalloids: 0.9% saline solution/HES: HEAfusine, B Braun Medical) (Table 1) . Randomisation was performed in blocks of eight by a computerised number generator list provided by a statistician not involved in the determination of eligibility or in the assessment of outcomes. The study packs were sealed in identical sequentially numbered boxes containing the entire treatment for each patient. Each "Iso-TC treatment packet" contained Isofundine or 0.9% saline solution (sheath labelled "crystalloid"), Tetraspan or HEAfusine (sheath labelled "HES"), and a sheet was also provided for the administration schedule. Patients, investigators, members of the monitoring board and medical and nursing staff were unaware of the patients' treatment assignment.
Conduct of the study
Administration of the studied solutions began immediately after patient admission and lasted 48 hours. The attributed crystalloid was administered as a continuous intravenous infusion (30 ml/kg/day). The attending physician could administer optional boli (20 ml/kg of the attributed crystalloid or 10 ml/kg of the attributed HES over 20 minutes). Apart from blood products, other intravenous fluids were not allowed during the first 48 hours. After the 48th hour, fluid infusions were not controlled.
General care for brain-injured patients
Brain-injured patients were mechanically ventilated and were sedated with fentanyl and midazolam (0.9% saline solution as drug-carrier solution). Patients were kept in a semirecumbent position. Continuous enteral nutrition was initiated 24 hours after brain injury [20] . The rate of enteral nutrition (Fresubin; Fresenius-Kabi, France) was increased every 8 hours until it reached 83 ml/h (2,000 kcal/day) (see Additional file 1 for full description). Parenteral nutrition was started on day 7 in patients intolerant to gastric feeding. Secondary brain injuries were prevented by avoiding hypoxaemia and anaemia (haemoglobin <10 g/dl), maintaining body temperature between 36.0°C and 37.0°C, ensuring normoglycaemia and normocapnia (between 4.6 and 5.5 kPa). ICP was monitored with an intraparenchymal probe placed in the most affected side (Codman; Johnson & Johnson, Raynham, MA, USA) in patients with severe brain injuries who had abnormal computed tomography (CT) scans and were considered at increased risk of ICH [21] . Extraventricular drainage was used in case of hydrocephalus detected on CT scans. Patients were monitored by invasive arterial pressure and mean arterial pressure (MAP) was measured up to the brain for the calculation of CPP. CPP was maintained above 60 mmHg with boli of the attributed isotonic solutions (crystalloid or HES; see Table 1 ) and continuous infusion of norepinephrine (diluted in 0.9% saline solution). Mannitol (bolus of 0.5 g/kg repeatable once in case of poor ICP control, ICP >20 mmHg, after 30 minutes; maximum dose: 1 g/kg) was used to control episodes of ICH. When control of ICH was poor, sodium thiopental was used with a loading dose (2 to 3 mg/kg) followed by continuous administration (2 to 3 mg/kg/h) adapted to ICP evolution and to serum level monitoring (blood level of thiopental between 20 and 30 μg/ml). A continuous infusion of HSS (20% saline solution) was started in case of refractory ICH [11] . When control of ICH was poor, decompressive craniectomy or therapeutic hypothermia was discussed with the neurosurgical team. The evolution of brain injuries was assessed by CT within the first 72 hours after brain injury.
Data handling
The following data were recorded: general characteristics, including demography, initial GCS score, WFNS grade, time from tracheal intubation to study inclusion, vasopressor therapy, fluid challenges and surgical procedures prior to inclusion. Natraemia, chloraemia, kalaemia, magnesemia, phosphatemia, ionized calcaemia, azotaemia, albuminaemia, osmolarity, lactataemia, arterial gases and haematocrit were measured immediately before and at 6, 12, 24, 36 and 48 hours after starting the treatment. The total volume of fluid administered and the evolution of ICP were recorded during the study period (48 hours). Episodes of ICH, modifications on the control CT (bleeding, herniation or brain swelling), osmotherapy and/or barbiturate use, transfusion, vasopressor use, time to achieve more than 50% of goal calories of enteral nutrition, duration of mechanical ventilation, length of ICU stay and mortality rate were also recorded in the ICU. Safety was assessed by recording adverse events.
Definitions
Strong ion difference (SID) was defined as (Na + + K + + Ca 2+ + Mg 2+ ) -(Cl -+ lactate) mEq/L [22] . Hyperchloraemic metabolic acidosis was defined as SID below 40 mEq/L associated with chloraemia above 108 mmol/L according to local laboratory normal ranges.
Endpoints
The primary endpoint was the occurrence of hyperchloraemic metabolic acidosis within 48 hours. The secondary outcomes were electrolyte status, ICP, rate of ICH episodes, volume of intravenous fluid, duration of vasopressor therapy, duration of mechanical ventilation, length of ICU stay and death in the ICU.
Statistical analysis
To the best of our knowledge, the incidence of hyperchloraemic acidosis in brain-injured patients has not been documented to date. We have thus performed a post hoc analysis of the chloraemia values collected in a study of TBI patients with ICH receiving HSS [11] . We found a 65% incidence of hyperchloraemia within the first four days in the ICU before any HSS infusion. The sample size needed to detect a 45% decrease in the incidence of hyperchloraemic acidosis, assuming a basal rate of 65% in a two-sided test performed with a statistical power of 85% and an α risk of 0.05, was 20 patients in each group in this pilot study. Taking into account exclusions, and in an attempt to keep the power of the study, 42 patients (21 patients in each group) were included. The full analysis set (FAS) of patients was the primary population used for statistical analysis of efficacy (perprotocol analysis) and was defined as all randomised patients treated with the study drug who did not receive forbidden therapy (HSS infusion). All randomised patients (the intention-to-treat (ITT) population) were analysed for the primary outcome and safety variables.
We first verified that in all patients the incidence of hyperchloraemic acidosis at 48 hours was significantly decreased in the balanced group compared with the control group using Fisher's exact test. Six patients experienced hyperchloraemic acidosis prior to inclusion (four in the saline group and two in the balanced group). We therefore decided a posteriori to perform two complementary sensitivity analyses. The first excluded patients with preexisting hyperchloraemic acidosis, the second censored the preinclusion biological values (SID, chloraemia) and the third consisted of evaluating the effect of balanced solutions on the primary outcome on the basis of a logrank test.
For secondary outcomes, linear mixed models were used with group effect, time effect and interaction between time effect and group effect. We first investigated the interaction between time effect and group effect. For the values with no significant interaction, the mean difference between groups within the study period was provided. For the value with a significant interaction between time effect and group effect, comparisons were performed independently and P values were calculated at each time point. Residual analysis was used to assess the appropriateness of the models (including normality and homoscedasticity). Nonparametric data are expressed as medians and interquartile ranges (IQRs). Categorical data are expressed as numbers and percentages. χ2 test, Fisher's exact test and Wilcoxon rank-sum test were used as appropriate.
A subgroup analysis considering severe TBI patients was performed a posteriori using the same analytical strategy. Regarding ICP evolution, subgroup analysis considering the 15 patients with ICH was performed. All statistical tests were two-sided. Statistical analyses were performed using SAS 9.1 statistical software (SAS Institute, Cary, NC, USA).
Results
Study population
Of the 42 patients included, 41 were included in the ITT analysis (one consent withdrawal) and 40 were included in the FAS analysis (exclusion of one patient who received HSS infusion within the first six hours; Figure 1 ). Demographic data are provided in Table 2  (see Additional file, Table S1 , for the demographics of the FAS population). The total volume of fluid infusion was not altered by study group (Table 3 ). The total amount of chloride infusion was lower in the balanced group than in the saline group (median 744 mmol (IQR = 572 to 952) and median 918 mmol (IQR = 689 to 1,148), respectively; P = 0.014) ( Table 3 ). Two patients in the saline group and one patient in the balanced group received one bolus of 500 ml of colloid diluted in a saline solution (Gelofusine; B Braun Medical) out of the study protocol, and data from these patients were kept in the statistical analysis.
Efficacy outcomes
In the ITT population, 19 patients (90%) in the saline group and 10 patients (50%) in the balanced group had hyperchloraemic acidosis within the first 48 hours (P = 0.004). The Kaplan-Meier estimators at hour 48 were 90% (range = 83% to 92%) in the saline group and 50% (range = 31% to 72%) in the balanced group, with a hazard ratio (HR) for hyperchloraemic acidosis in the balanced group of 0.24 (95% CI = 0.10 to 0.59; P = 0.003) (Figure 2A ).
In the FAS analysis, 18 patients (90%) in the saline group and 10 patients (50%) in the balanced group had hyperchloraemic acidosis within the first 48 hours (P = 0.01). The Kaplan-Meier estimators at hour 48 were 90% (range = 73% to 98%) in the saline group and 50% (range = 31% to 72%) in the balanced group, with a HR for hyperchloraemic acidosis in the balanced group of 0.28 (95% CI = 0.11 to 0.70; P = 0.006) ( Figure 2B ). Two sensitivity analyses did not change the results. The HR for hyperchloraemic acidosis in the balanced group was 0.18 (95% CI = 0.06 to 0.55; P = 0.002) when the patients with acidosis prior to inclusion were excluded, and it was 0.25 (95% CI = 0.09 to 0.69; P = 0.008) with a censorship of the biological values (SID, chloraemia) prior to inclusion. In the subgroup of TBI patients, the HR for hyperchloraemic acidosis in the balanced group was 0.30 (95% CI = 0.12 to 0.80; P = 0.015) ( Figure 2C ).
Secondary efficacy outcomes
The pH was lower in the saline group than in the balanced group (mean difference = -0.03 (-0.05 to -0.01); P = 0.004) ( Figure 3A) . Patients in the saline group had a lower SID than the balanced group (mean difference = -1.55 mEq/L (-3.09 to -0.02); P = 0.047) ( Figure 3B ). Chloraemia was higher in the saline group than in the balanced group (mean difference = 4.8 mmol/L (1.9 to 7.6); P = 0.002) ( Figure 3C ). Compared with the balanced group, patients in the saline group had lower phosphataemia (mean difference = -0.12 mmol/L [-0.21 to -0.04); P = 0.008) ( Figure 3D ). From hour 0 to hour 48, albuminaemia and partial pressure of carbon dioxide in arterial blood (PaCO 2 ) were not altered in the saline group compared with the balanced group ( Figures 3E and 3F ). The reported differences in the acid-base status between groups were not significantly modified in the subgroup of TBI patients (Additional file, Figure S1 ). The results for base excess, effective SID, simplified anion gap and corrected anion gap are provided in the Additional file, Table S2 . The blood osmolarity was higher in the saline group than in the balanced group (mean difference = 7 mOsmol/L (1 to 14); P = 0.024) ( Figure 4A ). The natraemia levels were higher in the saline group than in the balanced group (mean difference = 2 mmol/L (0 to 4); P = 0.036) ( Figure 4B ). ICP was not altered in the study group (mean difference = 4 mmHg (-1 to 8); P = 0.088) ( Figure 4C ). In the subgroup of TBI patients, blood osmolarity, natraemia and ICP were not altered in the study group (see Additional file, Figure S2 ). Among the entire population, seven patients (35%) in the saline group and eight patients (40%) in the balanced group developed ICH (P = 0.744) ( Table 4 ). In the subgroup of patients who developed ICH, ICP was not altered by study group (mean difference = -4 mmHg (-11 to 2); P = 0.20). (Additional file, Figure S3 ).
Safety assessment
Safety outcomes were assessed for the ITT patient population ( Table 4 ). Decompressive craniectomy was Hydroxyethyl starch solutions (ml) H0 to H6 0 (0 to 500) 0 (0 to 500) 0.613 H6 to H24 0 (0 to 500) 0 (0 to 500) 0.563 H24 to H48 0 (0 to 0) 500 (0 to 1,000) 0.060 H0 to H48 500 (0 to 1,500) 1,000 (500 to 1,500) 0.228 performed before ICU admission in one patient (5%) in the balanced group compared with one patient (5%) in the saline group (P = 0.972) ( Table 4 ). Three patients (14%) in the saline group died (two with ICH (10%) and one due to care withdrawal (5%)), compared with five patients (25%) in the balanced group (two patients with ICH (10%) and three patients due to care withdrawal (15%)) (P = 0.387). No patients died during the study periodThere is no need to provide this information since it is stated that 3 patients died in the saline group and five in the other group.
Discussion
The present study shows that balanced solutions, in comparison with isotonic saline solutions, reduced the occurrence of hyperchloraemic acidosis in brain-injured patients. Balanced solutions were not associated with ICP alteration or ICH episodes. According to Stewart et al., hydrogen ion concentration (pH) is independently influenced by three biological variables: (1) PaCO 2 , (2) total weak acid concentration (labelled A tot ) composed of phosphate and albumin and (3) SID corresponding to the difference between strong cations and strong anions [22] . According to Stewart et al.'s concept, sodium chloride solutions are responsible for metabolic acidosis through a decrease in SID [23] [24] [25] . Thus, administration of drugs with sodium chloride excipient (such as cloxacillin, midazolam or fentanyl) participate in the decrease in SID, which could partially explain the 50% rate of hyperchloraemic acidosis in the balanced group. The concentration of chloride in 0.9% saline solutions surpasses the normal ranges for blood chloraemia [26] . A correlation between hyperchloraemia and base excess has been described in patients undergoing major surgery [16] . Balanced solutions reduce the risk of hyperchloraemic acidosis in elderly patients undergoing major surgery [27, 28] . Our results reveal that balanced solutions decrease the risk of hyperchloraemic acidosis in patients with severe brain injury.
At this time, there is increasing evidence that chloriderich solutions alter the outcomes of critical ill patients [9] . In animal models, chloride-rich solutions decreased the glomerular filtration rate by inducing renal vasoconstriction [29, 30] . In a before-after study, the restriction of chloride-rich solutions was associated with a decrease in kidney failure in critically ill patients [10] . Saline-rich solutions alter the coagulation cascade and increase intraoperative blood loss when compared with balanced solutions [31] [32] [33] [34] . Hyperchloraemic acidosis also decreases gastric and pyloric motility and could reduce gastric mucosal perfusion [28] . In the present study, balanced solutions prevented hyperchloraemic acidosis but altered neither kidney function (assessed by diuresis and azotaemia) nor gut motility (assessed by the time to achieve more than 50% of enteral nutrition goal calories).
Prevention of hypo-osmolarity is a major goal for the prevention and treatment of ICH. Indeed, hypo-osmolarity induces brain ischaemia resulting from the swelling of perivascular astrocytic cells and also increases ICP and the volume of brain injury [35] . Thus, administration of hypoosmolar solutions should be avoided in brain-injured patients [6, 7] . The isotonicity of the balanced solutions may authorize their utilization in the neuro-ICU, but few data are available in this setting to date. In the present study, the balanced solutions failed to induce hyperosmolarity, and the blood osmolarity was lower in the balanced group than in the saline group. This lower osmolarity in the balanced group may prove important because the maintenance of normal osmolarity is an asset when caring for the brain-injured patients. However, neither ICP evolution nor the rate of ICH were different between the study groups. These results could be explained by the impact of balanced solutions on chloraemia, which is a key regulator of cell volume [10] . Chloride ion efflux prevents cell swelling in hypotonic media [12, 36] . The lower chloraemia observed in the balanced group could have increased the phenomenon of chloride ion efflux, limiting brain swelling despite decreased osmolarity compared with the saline group. According to this hypothesis, it has previously been described that a sodium lactate-based hyperosmolar solution more significantly decreased ICP than an equivalent osmotic load of chloride-rich solution [35] . Prevention of hyperchloraemia appears to be an asset for the prevention of ICH in patients with severe brain injury.
There is a controversy about the safety of HES, particularly regarding its effects on coagulation [37] . These concerns could prove to be important in the setting of brain-injured patients. Recently, the Neuro-Intensive Care and Emergency Medicine (NICEM) Section of the European Society of Intensive Care Medicine consensus document stated that HES is not recommended in the context of brain injury [38] . However, this consensus statement was not available when our study started. Moreover, the doses of HES used in each group in our study were below the maximum daily threshold of 20 ml/kg/day. This study has several limitations. First, given the small number of included SAH patients, the conclusions are valid mainly for the TBI patients. Second, we did not report any differences between groups regarding side effects of hyperchloraemic acidosis. Third, the reported biological differences may not be clinically relevant. Prolonged infusion of 0.9% saline solution may alter clinical outcomes. Fourth, the balanced solution did not alter neurological recovery, and we cannot rule out the theoretical issue regarding the risk of ICH with balanced solutions. However, this pilot study was not powered to evaluate these endpoints.
Conclusions
The use of balanced solutions reduces the incidence of hyperchloraemic acidosis in brain-injured patients. ICP evolution and the rate of ICH in brain-injured patients did not appear to be different between groups. The safety and impact of balanced solutions on neurological recovery, as well as the potential side effects of balanced solutions, should be investigated in a large, randomised trial comparing balanced solutions and isotonic saline solutions in TBI patients. Volteau) of UHN performed the statistical analysis. The local pharmacist (Laurent Flet) blinded the solutions. The results were presented (abstract) at the 53th congress of the French Congress of Anaesthesia and Critical Care Medicine (SFAR 2011).
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